ATE315939T1 - Verfahren zur prophylaxe oder kontrolle des katarakts - Google Patents

Verfahren zur prophylaxe oder kontrolle des katarakts

Info

Publication number
ATE315939T1
ATE315939T1 AT95900556T AT95900556T ATE315939T1 AT E315939 T1 ATE315939 T1 AT E315939T1 AT 95900556 T AT95900556 T AT 95900556T AT 95900556 T AT95900556 T AT 95900556T AT E315939 T1 ATE315939 T1 AT E315939T1
Authority
AT
Austria
Prior art keywords
cataract
prophylaxis
control
tgfbeta
relates
Prior art date
Application number
AT95900556T
Other languages
English (en)
Inventor
Johnston William Mcavoy
Coral Gwenda Chamberlain
Original Assignee
Univ Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sydney filed Critical Univ Sydney
Application granted granted Critical
Publication of ATE315939T1 publication Critical patent/ATE315939T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Prostheses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95900556T 1993-11-19 1994-11-11 Verfahren zur prophylaxe oder kontrolle des katarakts ATE315939T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPM254093 1993-11-19

Publications (1)

Publication Number Publication Date
ATE315939T1 true ATE315939T1 (de) 2006-02-15

Family

ID=3777368

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95900556T ATE315939T1 (de) 1993-11-19 1994-11-11 Verfahren zur prophylaxe oder kontrolle des katarakts

Country Status (6)

Country Link
US (1) US20030130324A1 (de)
EP (1) EP0735895B1 (de)
JP (1) JPH09505057A (de)
AT (1) ATE315939T1 (de)
DE (1) DE69434617D1 (de)
WO (1) WO1995013827A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
EA001745B1 (ru) * 1996-10-14 2001-08-27 Киссеи Фармасьютикал Ко., Лтд. Ингибитор вторичной катаракты
AUPO427196A0 (en) 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
NZ540885A (en) * 2002-12-20 2009-02-28 Chakshu Res Inc Ophthalmic formulation for the prevention and treatment of ocular conditions
US20060166879A1 (en) * 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7794697B2 (en) * 2004-06-30 2010-09-14 Abbott Medical Optics Inc. Enhancement of lens regeneration using materials comprising polysiloxane polymers
US20080075756A1 (en) * 2004-06-30 2008-03-27 Advanced Medical Optics, Inc. Enhancement of lens regeneration using materials comprising polymers
US8802651B2 (en) * 2004-06-30 2014-08-12 Abbott Medical Optics Inc. Hyaluronic acid in the enhancement of lens regeneration
US20060083732A1 (en) * 2004-06-30 2006-04-20 Arlene Gwon Hyaluronic acid in the enhancement of lens regeneration
EA200800338A1 (ru) * 2005-07-15 2008-08-29 Чакшу Рисерч Инк. Профилактика и лечение офтальмологических осложнений диабета
US8506944B2 (en) 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
CN105664136A (zh) * 2008-05-07 2016-06-15 加利福尼亚大学董事会 眼表润滑的治疗性补充和富集
EP2340309A2 (de) 2008-09-22 2011-07-06 Rxi Pharmaceuticals Corporation Neutrale nanotransporter
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
JP2013513622A (ja) 2009-12-14 2013-04-22 ユニバーシティ オブ マサチューセッツ 白内障及び老眼を阻害する方法
CN106074591B (zh) 2010-03-24 2020-01-14 菲奥医药公司 眼部症候中的rna干扰
BR112012024049A2 (pt) 2010-03-24 2017-03-01 Rxi Pharmaceuticals Corp interferência de rna em indicações dérmicas e fibróticas
CN105209033B (zh) 2013-03-14 2018-09-18 马萨诸塞大学 抑制白内障和老花眼的方法
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
CN108348494A (zh) 2015-11-13 2018-07-31 马萨诸塞大学 用于抑制白内障和老花眼的含peg的双官能分子

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61233622A (ja) * 1985-04-09 1986-10-17 Riken Vitamin Co Ltd 眼薬組成物
SU1500254A1 (ru) * 1986-01-10 1989-08-15 Ростовский медицинский институт Способ прогнозировани осложнений после операции экстракции стационарных травматических катаракт
CA1322526C (en) * 1987-06-04 1993-09-28 John I. Clark Chemical prevention or reversal of cataract by phase separation inhibitors
US5290813A (en) * 1987-06-04 1994-03-01 Massachusetts Institute Of Technology Chemical prevention or reversal of cataract by phase separation inhibitors
US5401880A (en) * 1987-06-04 1995-03-28 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
US5338545A (en) * 1987-06-04 1994-08-16 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
FR2627078B1 (fr) * 1988-02-16 1994-03-18 Allergan Inc Dispositif oculaire
DE68921436T2 (de) * 1988-12-09 1995-08-10 Allergan Inc Verwendung von 2-substituierten Thiazolidin-4-carbonsäuren zur Behandlung von Katarakt.
CA2066660C (en) * 1989-09-15 2002-07-30 Cary Reich Method for achieving epithelialization of synthetic lenses
EP0775742A3 (de) * 1989-09-29 1998-01-14 La Jolla Cancer Research Foundation Inhibierung von TGF-beta zur Verhinderung von extrazellulärer Matrixanhäufung
TW224942B (de) * 1990-04-04 1994-06-11 Adka Ueno Kk
US5164187A (en) * 1990-04-05 1992-11-17 Norian Corporation Hydroxyapatite prosthesis coatings
ATE139683T1 (de) * 1990-12-03 1996-07-15 Adatomed Pharma Chiron Intraokulare künstliche augenlinse
IT1249047B (it) * 1991-02-21 1995-02-11 Zambon Spa Composizione farmaceutica per il trattamento della cataratta
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
IT1251838B (it) * 1991-09-20 1995-05-26 Lpb Ist Farm Uso della nimesulide nel trattamento della cataratta
AU669132B2 (en) * 1991-10-11 1996-05-30 Mark Cedric Gillies Treating ophthalmic fibrosis using interferon-alpha
WO1993009800A1 (en) * 1991-11-14 1993-05-27 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
JP3854307B2 (ja) * 1991-12-04 2006-12-06 ザ バーナム インスティテュート 細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害
WO1993019783A1 (en) * 1992-04-01 1993-10-14 The Whittier Institute For Diabetes And Endocrinology Methods of inhibiting or enhancing scar formation in the cns
WO1993021945A1 (en) * 1992-04-23 1993-11-11 The Regents Of The University Of California METHODS FOR TREATING VASCULAR DISORDERS BY INHIBITING THE ENDOTHELIN STIMULATORY ACTIVITY OF TGF$g(b)
EP0651650A4 (de) * 1992-07-08 1996-04-17 Celtrix Pharma METHODE ZUR BEHANDLUNG VON AUGENKRANKHEITEN MITTELS TGF--g(b).
US5589464A (en) * 1992-09-01 1996-12-31 Allergan Use of 2-substituted-thiazolidine-4-carboxylic acids for treatment of cataract
CA2146973C (en) * 1992-10-29 2008-09-02 Patricia R. Segarini Uses of tgf-.beta. receptor fragment as a therapeutic agent
AU5541094A (en) * 1992-10-30 1994-05-24 Consejo Superior De Investigaciones Cientificas Compositions and methods for modifying the regulatory activity of tgf-beta
TW354762B (en) * 1993-02-23 1999-03-21 Otsuka Pharma Co Ltd Agent for prophylaxis or treatment of cataract
WO1994026303A1 (en) * 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5665770A (en) * 1993-11-05 1997-09-09 Gakko Hojin Kinki Daigaku Method for treatment of cataract with radical scavenger
US6673341B2 (en) * 1998-07-06 2004-01-06 Beth Israel Deaconness Medical Center Methods of inhibiting proliferative diseases by inhibiting TGF-β-mediated angiogenesis

Also Published As

Publication number Publication date
WO1995013827A1 (en) 1995-05-26
EP0735895A4 (de) 2001-03-28
EP0735895A1 (de) 1996-10-09
JPH09505057A (ja) 1997-05-20
US20030130324A1 (en) 2003-07-10
DE69434617D1 (de) 2006-04-06
EP0735895B1 (de) 2006-01-18

Similar Documents

Publication Publication Date Title
DE69434617D1 (de) Verfahren zur prophylaxe oder kontrolle des katarakts
MX9206794A (es) Uso de acido salicilico para regular arrugas en lapiel y/o atrofia de la piel.
DE59807122D1 (de) Verwendung von fumarsäurederivaten zur behandlung von autoimmunerkrankungen
AU6008894A (en) Hypolipidaemic compounds
PL307527A1 (en) Crosslinked polymeric ammonium salts
DE69423782D1 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
AU1305295A (en) Skin tanning compositions
NO942351D0 (de)
DE69625696D1 (de) Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus
ES2138153T3 (es) Polieter poliamino metilen fosfonatos para el control de depositos con ph elevado.
DE69727839D1 (de) Verwendung von zusammensetzungen zur versorgung mit mineralien nach einer gastrotomie
DE69416166D1 (de) Verfahren zur regulierung von sialinsaeurederivaten in rekombinanten glykoproteinen
DE69510775D1 (de) Methoden zur verwendung von cyclischenpolyanionischen polyderivatenzur kontrolle von hautfalten
ATE317442T1 (de) Verfahren zur züchtung von mikroorganismen die methanol metabolisieren
ATE148074T1 (de) Verfahren zur kontrolle von schwingungen einer pendelnden last und vorrichtung zur durchführung des verfahrens
BG98761A (en) Substituted pyrroles
EP0591378A4 (de) Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie.
GB9410639D0 (en) Method of improving fertilization
ATE185682T1 (de) Für die vermeidung/begrenzung von mikrobiologisch beeinflusster korrosion und verfärbung verwendbare borate
DE69533807D1 (de) Verwendung des pilzes gliocadium catenulatun zur biologischen kontrolle von pflanzenkrankheiten
EP0321221A3 (de) Methode zur Vorbeugung oder Behandlung von Angstzuständen unter Einsatz eines ACE-Hemmstoffes
AU2001254634A1 (en) Use of neuregulin-beta as an indicator and/or target
HU9204171D0 (en) Method for producing aralkyl esters of 4,5-dihydroxi-9,10-dihydro-9,10-dioxo-2-anthracene-carboxylic acid as well as medical preparatives containing them
DE69210286D1 (de) Behandlung von intraocularem Druck mit einer synergistischen Kombination
DE69013077D1 (de) Zusammensetzung zur Regulation des Pflanzenwachstums.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties